Cargando…

Dostarlimab: A breakthrough in the field of oncology

Of the 19 million cancer cases reported worldwide in 2020, colorectal cancer (CRC) has a 10% prevalence and 9.4% mortality. A critical lack of cancer treatment facilities in third-world countries like Pakistan where a significant prevalence of CRC has been detected. The five FDA-approved drugs used...

Descripción completa

Detalles Bibliográficos
Autores principales: Hussain, Hassan ul, Burney, Muhammad Husban, Rehan, Syeda Tayyaba, Hasan, Mohammad Mehedi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9422050/
https://www.ncbi.nlm.nih.gov/pubmed/36045764
http://dx.doi.org/10.1016/j.amsu.2022.104046
_version_ 1784777731548905472
author Hussain, Hassan ul
Burney, Muhammad Husban
Rehan, Syeda Tayyaba
Hasan, Mohammad Mehedi
author_facet Hussain, Hassan ul
Burney, Muhammad Husban
Rehan, Syeda Tayyaba
Hasan, Mohammad Mehedi
author_sort Hussain, Hassan ul
collection PubMed
description Of the 19 million cancer cases reported worldwide in 2020, colorectal cancer (CRC) has a 10% prevalence and 9.4% mortality. A critical lack of cancer treatment facilities in third-world countries like Pakistan where a significant prevalence of CRC has been detected. The five FDA-approved drugs used for CCR therapy (Durvalumab, Atezolizumab, Nivolumab, Pembrolizumab, and Avelumab) have been associated with a high occurrence of grade 3-4 adverse side effects. Dostarlimab is a new drug previously used to treat endometrial cancers and has a mechanism of action that is in accordance with other PD-1/PD-L1 inhibitors. A recent clinical trial has found Dostarlimab to cure 100% of the CRC patients who were given this drug while also showing no adverse events of grade 3 or higher in any patient. The recent clinical trial has opened up doors for future clinical trials perhaps with bigger sample sizes and ones that also include CRC patients belonging to wider geo-economic backgrounds such as those of Pakistan and other Asian countries.
format Online
Article
Text
id pubmed-9422050
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-94220502022-08-30 Dostarlimab: A breakthrough in the field of oncology Hussain, Hassan ul Burney, Muhammad Husban Rehan, Syeda Tayyaba Hasan, Mohammad Mehedi Ann Med Surg (Lond) Short Communication Of the 19 million cancer cases reported worldwide in 2020, colorectal cancer (CRC) has a 10% prevalence and 9.4% mortality. A critical lack of cancer treatment facilities in third-world countries like Pakistan where a significant prevalence of CRC has been detected. The five FDA-approved drugs used for CCR therapy (Durvalumab, Atezolizumab, Nivolumab, Pembrolizumab, and Avelumab) have been associated with a high occurrence of grade 3-4 adverse side effects. Dostarlimab is a new drug previously used to treat endometrial cancers and has a mechanism of action that is in accordance with other PD-1/PD-L1 inhibitors. A recent clinical trial has found Dostarlimab to cure 100% of the CRC patients who were given this drug while also showing no adverse events of grade 3 or higher in any patient. The recent clinical trial has opened up doors for future clinical trials perhaps with bigger sample sizes and ones that also include CRC patients belonging to wider geo-economic backgrounds such as those of Pakistan and other Asian countries. Elsevier 2022-07-05 /pmc/articles/PMC9422050/ /pubmed/36045764 http://dx.doi.org/10.1016/j.amsu.2022.104046 Text en © 2022 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Short Communication
Hussain, Hassan ul
Burney, Muhammad Husban
Rehan, Syeda Tayyaba
Hasan, Mohammad Mehedi
Dostarlimab: A breakthrough in the field of oncology
title Dostarlimab: A breakthrough in the field of oncology
title_full Dostarlimab: A breakthrough in the field of oncology
title_fullStr Dostarlimab: A breakthrough in the field of oncology
title_full_unstemmed Dostarlimab: A breakthrough in the field of oncology
title_short Dostarlimab: A breakthrough in the field of oncology
title_sort dostarlimab: a breakthrough in the field of oncology
topic Short Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9422050/
https://www.ncbi.nlm.nih.gov/pubmed/36045764
http://dx.doi.org/10.1016/j.amsu.2022.104046
work_keys_str_mv AT hussainhassanul dostarlimababreakthroughinthefieldofoncology
AT burneymuhammadhusban dostarlimababreakthroughinthefieldofoncology
AT rehansyedatayyaba dostarlimababreakthroughinthefieldofoncology
AT hasanmohammadmehedi dostarlimababreakthroughinthefieldofoncology